Value of plasma neurofilament light chain for monitoring efficacy in children with later-onset spinal muscular atrophy under nusinersen treatment

Clin Chem Lab Med. 2024 Feb 20;62(6):e132-e135. doi: 10.1515/cclm-2023-1119. Print 2024 May 27.

Authors

Jianing Jin¹, Yijie Feng¹, Siyi Huang¹, Yiqin Cui¹, Liya Jiang¹, Yue Yan¹, Yicheng Yu¹, Dongming Zhou², Feng Gao¹, Shanshan Mao¹

Affiliations

¹ Department of Neurology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, P.R. China.
² Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, P.R. China.

PMID: 38373071
DOI: 10.1515/cclm-2023-1119

No abstract available

Keywords: biomarker; children; neurofilament light chain; spinal muscular atrophy.

Publication types

Letter

MeSH terms

Child
Child, Preschool
Female
Humans
Infant
Male
Muscular Atrophy, Spinal* / blood
Muscular Atrophy, Spinal* / drug therapy
Neurofilament Proteins* / blood
Oligonucleotides* / therapeutic use
Treatment Outcome

Substances

nusinersen
Oligonucleotides
Neurofilament Proteins
neurofilament protein L